A Location-Adaptive Four-Stage Hybrid Therapeutic Platform for Minimally Invasive Spatial Control of Glioblastoma (GBM) with Computational Simulation

Abstract Glioblastoma (GBM) is an aggressive primary malignant brain tumor that infiltrates normal brain parenchyma along white matter tracts and perivascular spaces (contact guidance) without distinct anatomical borders, leading to frequent local recurrence near the resection margin. Moreover, anatomical constraints and recurrence pathways differ substantially between superficial cortical lesions (frontal, temporal, and parietal lobes) and deep-seated lesions (thalamus, basal ganglia, and periventricular regions). This paper proposes a location-adaptive, four-stage hybrid therapeutic platform designed for minimally invasive spatial control of GBM across any intracranial location, guided by preoperative diffusion tensor imaging (DTI) tractography. The protocol comprises: (1) MRI-monitored core cytoreduction (partial cryoablation or laser interstitial thermal therapy [LITT]) paired with slow fractional drainage; (2) 5-aminolevulinic acid (5-ALA) blue-light fiber-optic endoscopic margin verification and directional anti-adhesion barrier coating (Push) over eloquent neural tracts; (3) location-adaptive CXCL12 chemotactic motility trapping (Pull) via either an aligned polycaprolactone (PCL) nanofiber conduit leading to a subcutaneous extracortical trap (Mode A: superficial lesions) or a periventricular thermosensitive hydrogel trap coupled to an Ommaya reservoir (Mode B: deep-seated lesions), enabling safe physical extraction or replacement without injuring healthy brain tissue; and (4) 200 kHz deep cross-fire tumor-treating fields (TTFields), 5-ALA sonodynamic therapy (SDT), and trap-harvested neoantigen-based immunotherapy (CAR-T / mRNA vaccines). To bridge the gap before next-generation biomaterials receive full regulatory approval, a near-term clinical translation roadmap utilizing currently approved medical devices and drugs—alongside a modular working-sheath catheter architecture designed to lower regulatory barriers—is also presented. Keywords: Glioblastoma (GBM), Location-Adaptive Therapy, Partial Cryoablation, LITT, 5-ALA Fluorescence & Sonodynamic Therapy (SDT), PCL Nanofiber Trap, CXCL12 Chemotaxis, Ommaya Reservoir, Convection-Enhanced Delivery (CED), Tumor-Treating Fields (TTFields)

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-13
DOI
https://doi.org/10.5281/zenodo.24199610
Primary Topic
Glioma Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A Location-Adaptive Four-Stage Hybrid Therapeutic Platform for Minimally Invasive Spatial Control of Glioblastoma (GBM) with Computational Simulation

Youngbae Lee
2 links
Zenodo (CERN European Organization for Nuclear Research)
Glioma Diagnosis and Treatment
preprint

A Location-Adaptive Four-Stage Hybrid Therapeutic Platform for Minimally Invasive Spatial Control of Glioblastoma (GBM) with Computational Simulation

Youngbae Lee
preprint en

Abstract

Abstract Glioblastoma (GBM) is an aggressive primary malignant brain tumor that infiltrates normal brain parenchyma along white matter tracts and perivascular spaces (contact guidance) without distinct anatomical borders, leading to frequent local recurrence near the resection margin. Moreover, anatomical constraints and recurrence pathways differ substantially between superficial cortical lesions (frontal, temporal, and parietal lobes) and deep-seated lesions (thalamus, basal ganglia, and periventricular regions). This paper proposes a location-adaptive, four-stage hybrid therapeutic platform designed for minimally invasive spatial control of GBM across any intracranial location, guided by preoperative diffusion tensor imaging (DTI) tractography. The protocol comprises: (1) MRI-monitored core cytoreduction (partial cryoablation or laser interstitial thermal therapy [LITT]) paired with slow fractional drainage; (2) 5-aminolevulinic acid (5-ALA) blue-light fiber-optic endoscopic margin verification and directional anti-adhesion barrier coating (Push) over eloquent neural tracts; (3) location-adaptive CXCL12 chemotactic motility trapping (Pull) via either an aligned polycaprolactone (PCL) nanofiber conduit leading to a subcutaneous extracortical trap (Mode A: superficial lesions) or a periventricular thermosensitive hydrogel trap coupled to an Ommaya reservoir (Mode B: deep-seated lesions), enabling safe physical extraction or replacement without injuring healthy brain tissue; and (4) 200 kHz deep cross-fire tumor-treating fields (TTFields), 5-ALA sonodynamic therapy (SDT), and trap-harvested neoantigen-based immunotherapy (CAR-T / mRNA vaccines). To bridge the gap before next-generation biomaterials receive full regulatory approval, a near-term clinical translation roadmap utilizing currently approved medical devices and drugs—alongside a modular working-sheath catheter architecture designed to lower regulatory barriers—is also presented. Keywords: Glioblastoma (GBM), Location-Adaptive Therapy, Partial Cryoablation, LITT, 5-ALA Fluorescence & Sonodynamic Therapy (SDT), PCL Nanofiber Trap, CXCL12 Chemotaxis, Ommaya Reservoir, Convection-Enhanced Delivery (CED), Tumor-Treating Fields (TTFields)

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon